Advanced Therapies Europe

#Advanced Therapies Europe #Bio Europe #Cell and gene therapy #Events

Industry insights from Spring 2025 events

Bio Europe Spring 2025 took place from 17-19 March in Milan, Italy, at the same time as Advanced Therapies London at the ExCel. Here, industry experts provided DDW’s Megan Thomas with insight from the events.   Bio Europe Spring Dr Carsten Rudolph, Cofounder and Chief Executive Officer at Ethris, said… Read More

#Exclusive Content

European map
#Advanced Therapies Europe #Biologics / Biotechnology #Cancer immunotherapy #CAR-T #Cell and gene therapy #Cell therapy #Collaboration #Europe #Immuno-oncology #Market reporting #Oncology #Start-ups

New podcast: Why is Europe a drug discovery epicentre?

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: European drug discovery and development success stories,… Read More

#News

Cell and gene therapies
#Advanced Therapies #Advanced Therapies Europe #Cell and gene therapy #Cell therapy #Gene therapy

Advanced Therapies Europe: From bench to bedside and boardroom

Advanced Therapies Europe took place from 9-12 September 2023 in Portugal. DDW’s Megan Thomas asked attendees: What is most important to scale from discovery to commercialisation of cell and gene therapies (CGTs)? Joel Eichmann, Co-Founder, Green Elephant Biotech It always comes down to time-to-market and risk… Read More

#Exclusive Content

#Advanced Therapies Europe #CAR-T #Cell and gene therapy #Cell therapy #Collaboration

On the European CGT landscape, zebras and the future of medicine

Listen to this article on the DDW podcast: Alongside industry professionals interested in the cell and gene therapy landscape in Europe, DDW’s Multimedia Editor Megan Thomas was welcomed to Advanced Therapies Europe 2022 by Phacilitate’s Vice President, Becky Johnson-Kent. Johnson-Kent introduced the notion of the zebra company… Read More

#Editor's Choice #Exclusive Content